Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q1 2026 revenue grew 16% YoY, commercial cell and gene therapy revenue grew 26%, full-year revenue guidance was raised to $192M-$196M, and the stock is up about 37% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Momentum Fade ⢠Breakout Holding ⢠Resistance Pressure Support Level: $15.06-$15.26 Resistance Level: $16.40-$16.60 CYRX remains constructively above its spring breakout zone, but the drop from 16.57 to 15.37 shows fading momentum and a higher risk of near-term consolidation unless it reclaims 16.0+.
Sentiment & News
Key News Insights: ⢠Earnings scheduled ⢠No performance data ⢠Routine disclosure CYRX's only recent news was a routine announcement that it will report Q2 2026 earnings on August 6 after market close, with no operating update or new strategic signal.
AI Summary
CYRX's Q1 revenue acceleration and raised 2026 guide show real demand momentum in cell and gene therapy, but the investment case now hinges on whether that growth can finally translate into margin expansion and free cash flow rather than just bigger, low-visibility revenue.
Description
Cryoport, Inc. provides temperature-controlled logistics and related services for life sciences customers across the Americas, Europe, the Middle East, Africa, and Asia Pacific. Its offerings include shipment management software, condition-monitoring and tracking tools, cryogenic transport equipment, and storage and handling services for biological materials. The company serves the biopharma, animal health, and human reproductive medicine markets and was founded in 1999 in Brentwood, Tennessee.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 6 | May 13 | CYRX | Cryoport, Inc. | Q1 2026 revenue grew 16% YoY, commercial cell and gene therapy revenue grew 26%, full-year revenue guidance was raised to $192M-$196M, and the stock is up about 37% over 21 trading days. | Closed | +4.4% |